People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial ...

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

The companies will deliver products for diabetes and weight control in specific nations across the Middle East.

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...